{"disease":{"id":"metastatic-colon-adenocarcinoma","name":"metastatic colon adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06864338","title":"Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test","phase":"","overall_status":"RECRUITING","enrollment_count":2700,"lead_sponsor_name":"Mainz Biomed","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03765736","title":"Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial","phase":"","overall_status":"TERMINATED","enrollment_count":199,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT05308446","title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04704661","title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04599140","title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04475159","title":"Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Prof. Aviram Nissan","has_results":false},{"nct_id":"NCT03415126","title":"A Study of ASN007 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Asana BioSciences","has_results":false},{"nct_id":"NCT04616183","title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04109924","title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT07407465","title":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Gruppo Oncologico del Nord-Ovest","has_results":false},{"nct_id":"NCT04362839","title":"Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04017650","title":"Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":38,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06414304","title":"Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"OncoAtlas LLC","has_results":false},{"nct_id":"NCT06929338","title":"xDRIVE in Metastatic Colorectal Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"First Ascent Biomedical Inc.","has_results":false},{"nct_id":"NCT05627635","title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06625515","title":"First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Accent Therapeutics","has_results":false},{"nct_id":"NCT05130060","title":"A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03992456","title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT04164069","title":"Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Anne Noonan","has_results":false},{"nct_id":"NCT04108481","title":"Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT03592641","title":"Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04044430","title":"Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05356897","title":"Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT06575725","title":"Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}